PriceTargets.com logo

Alcon - ALC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $90.97
  • Forecasted Upside: 15.19%
  • Number of Analysts: 20
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 11 Buy Ratings
  • 1 Strong Buy Ratings
$78.97 As of 12/4/2025 04:59 PM ET
▼ -1.06 (-1.32%)

This chart shows the closing price for ALC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alcon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALC

Analyst Price Target is $90.97
▲ +15.19% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for Alcon in the last 3 months. The average price target is $90.97, with a high forecast of $101.09 and a low forecast of $77.53. The average price target represents a 15.19% upside from the last price of $78.97.

This chart shows the closing price for ALC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 20 investment analysts is to moderate buy stock in Alcon. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/28/2025CitigroupReiterated RatingBuy ➝ Buy
11/24/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/24/2025BTIG ResearchReiterated RatingBuy ➝ Buy$91.00
11/17/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/14/2025Sanford C. BernsteinReiterated RatingOutperform ➝ Outperform$101.09
11/13/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$95.00 ➝ $98.00
11/12/2025Needham & Company LLCLower TargetBuy ➝ Buy$101.00 ➝ $98.00
11/11/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/11/2025MizuhoLower TargetOutperform ➝ Outperform$110.00 ➝ $100.00
11/5/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/28/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/22/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/21/2025KeyCorpLower TargetOverweight ➝ Overweight$98.00 ➝ $91.00
10/14/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/13/2025UBS GroupSet Target$91.00
10/13/2025BarclaysInitiated CoverageEqual Weight$86.00
10/13/2025BarclaysInitiated CoverageEqual Weight$86.00
10/13/2025BTIG ResearchLower TargetBuy ➝ Buy$92.00 ➝ $91.00
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/29/2025Stifel NicolausLower TargetBuy ➝ Buy$90.00 ➝ $85.00
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
8/26/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform
8/21/2025MizuhoLower TargetOutperform ➝ Outperform$120.00 ➝ $110.00
8/21/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$84.00 ➝ $80.00
8/21/2025Robert W. BairdLower TargetOutperform ➝ Outperform$108.00 ➝ $95.00
8/21/2025JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$105.88 ➝ $77.53
8/21/2025Stifel NicolausLower TargetBuy ➝ Buy$100.00 ➝ $90.00
8/20/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$107.00
8/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$107.00
8/6/2025Wells Fargo & CompanyReiterated RatingEqual Weight$93.00
7/15/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$90.00 ➝ $84.00
7/14/2025BTIG ResearchSet TargetBuy ➝ Buy$100.00
5/22/2025Kepler Capital MarketsUpgradeHold ➝ Strong-Buy
5/20/2025Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
5/14/2025BTIG ResearchLower TargetBuy$102.00 ➝ $99.00
5/14/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$110.00 ➝ $110.00
3/31/2025KeyCorpBoost TargetOverweight ➝ Overweight$108.00 ➝ $112.00
3/28/2025MizuhoBoost TargetOutperform ➝ Outperform$115.00 ➝ $120.00
3/28/2025Needham & Company LLCBoost TargetBuy ➝ Buy$107.00 ➝ $110.00
3/25/2025HSBCDowngradeHold
3/25/2025Hsbc Global ResDowngradeStrong-Buy ➝ Hold
3/25/2025Bank of AmericaUpgradeNeutral ➝ Buy
3/20/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$107.00 ➝ $107.00
2/27/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$104.00 ➝ $108.00
2/26/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$106.00 ➝ $106.00
1/24/2025KeyCorpLower TargetOverweight ➝ Overweight$107.00 ➝ $105.00
1/24/2025Needham & Company LLCLower TargetBuy ➝ Buy$108.00 ➝ $106.00
1/10/2025Redburn AtlanticUpgradeNeutral ➝ Buy
12/17/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$103.00 ➝ $108.00
11/26/2024BTIG ResearchDowngradeStrong-Buy ➝ Hold
11/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$107.00 ➝ $107.00
10/15/2024KeyCorpBoost TargetOverweight ➝ Overweight$103.00 ➝ $107.00
10/14/2024BTIG ResearchBoost TargetBuy ➝ Buy$104.00 ➝ $106.00
10/10/2024Redburn AtlanticUpgradeSell ➝ Neutral
9/12/2024BTIG ResearchBoost TargetBuy ➝ Buy$98.00 ➝ $104.00
9/10/2024Royal Bank Of CanadaUpgradeSector Perform ➝ Outperform
8/22/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$94.00 ➝ $105.00
8/22/2024OppenheimerBoost TargetOutperform ➝ Outperform$103.00 ➝ $110.00
8/22/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$104.00 ➝ $110.00
8/22/2024BTIG ResearchBoost TargetBuy ➝ Buy$96.00 ➝ $98.00
8/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$101.00 ➝ $101.00
8/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$101.00 ➝ $101.00
7/15/2024BTIG ResearchBoost TargetBuy ➝ Buy$92.00 ➝ $96.00
7/15/2024Morgan StanleyUpgradeUnderweight ➝ Equal Weight$65.00 ➝ $85.00
7/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$101.00 ➝ $101.00
5/15/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$89.00 ➝ $94.00
5/15/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$95.00 ➝ $104.00
5/15/2024Stifel NicolausReiterated RatingBuy ➝ Buy$95.00 ➝ $100.00
5/15/2024MizuhoBoost TargetBuy ➝ Buy$100.00 ➝ $105.00
5/15/2024OppenheimerUpgradeMarket Perform ➝ Outperform$103.00
5/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$98.00 ➝ $98.00
4/22/2024Stifel NicolausReiterated RatingBuy ➝ Buy$95.00 ➝ $95.00
4/10/2024The Goldman Sachs GroupInitiated CoverageBuy$100.00
3/14/2024Royal Bank Of CanadaInitiated CoverageSector Perform
3/13/2024Stifel NicolausReiterated RatingBuy ➝ Buy$95.00
3/4/2024ArgusBoost TargetBuy ➝ Buy$90.00 ➝ $100.00
3/1/2024MizuhoBoost TargetBuy ➝ Buy$92.00 ➝ $100.00
2/29/2024KeyCorpBoost TargetOverweight ➝ Overweight$87.00 ➝ $92.00
2/29/2024Sanford C. BernsteinBoost TargetOutperform ➝ Outperform$93.00 ➝ $96.60
2/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$86.00
2/6/2024KeyCorpInitiated CoverageOverweight$87.00
1/30/2024Robert W. BairdReiterated RatingOutperform ➝ Outperform$94.00
1/23/2024Sanford C. BernsteinInitiated CoverageOutperform$94.40
12/18/2023Redburn AtlanticDowngradeNeutral ➝ Sell
12/12/2023Stifel NicolausInitiated CoverageBuy$85.00
12/6/2023ArgusLower TargetBuy ➝ Buy$95.00 ➝ $90.00
12/4/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$85.00 ➝ $65.00
11/20/2023Jefferies Financial GroupLower TargetBuy ➝ Buy$94.00 ➝ $88.00
11/15/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$98.00
9/11/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$98.00
9/8/2023ArgusBoost TargetBuy ➝ Buy$90.00 ➝ $95.00
8/17/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$80.00 ➝ $89.00
8/17/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$90.00 ➝ $95.00
8/17/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$79.80 ➝ $89.30
8/14/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$94.00
7/17/2023BTIG ResearchBoost Target$88.00 ➝ $91.00
5/11/2023MizuhoBoost Target$85.00 ➝ $95.00
5/10/2023BTIG ResearchBoost Target$81.00 ➝ $88.00
5/10/2023Robert W. BairdUpgradeNeutral ➝ Outperform$75.00 ➝ $90.00
4/17/2023BTIG ResearchBoost TargetBuy$78.00 ➝ $81.00
4/10/2023Needham & Company LLCReiterated RatingBuy$85.00
3/29/2023MizuhoReiterated RatingBuy$85.00
3/6/2023Needham & Company LLCReiterated RatingBuy$85.00
3/1/2023Societe GeneraleUpgradeSell ➝ Hold
3/1/2023Robert W. BairdLower TargetNeutral$80.00 ➝ $75.00
2/28/2023Needham & Company LLCReiterated RatingBuy$85.00
2/3/2023Needham & Company LLCReiterated RatingBuy$85.00
12/22/2022MizuhoInitiated CoverageBuy$85.00
12/21/2022BTIG ResearchBoost TargetBuy$75.00 ➝ $78.00
11/21/2022Credit Suisse GroupLower TargetCHF 84 ➝ CHF 80
11/17/2022Societe GeneraleDowngradeHold ➝ Sell
11/17/2022Morgan StanleyBoost TargetEqual Weight$71.00 ➝ $78.00
11/17/2022Wells Fargo & CompanyLower Target$90.00 ➝ $83.00
11/17/2022CitigroupBoost TargetNeutral$67.00 ➝ $69.00
10/17/2022BTIG ResearchLower TargetBuy$80.00 ➝ $75.00
10/11/2022Morgan StanleyLower TargetEqual Weight$81.00 ➝ $71.00
10/5/2022CitigroupLower Target$73.00 ➝ $67.00
9/8/2022Credit Suisse GroupLower TargetCHF 96 ➝ CHF 84
8/16/2022UBS GroupLower TargetCHF 88 ➝ CHF 83.80
8/11/2022Societe GeneraleDowngradeBuy ➝ Hold
8/11/2022Morgan StanleyLower TargetEqual Weight$83.00 ➝ $81.00
8/11/2022Needham & Company LLCLower TargetBuy$87.00 ➝ $85.00
6/27/2022Deutsche Bank AktiengesellschaftLower TargetCHF 85 ➝ CHF 80
5/12/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ NeutralCHF 69 ➝ CHF 68.80
5/12/2022StephensUpgradeEqual Weight ➝ Overweight$86.00 ➝ $92.00
4/8/2022Needham & Company LLCInitiated CoverageBuy$95.00
3/11/2022Bank of AmericaInitiated CoverageBuy$85.00
2/18/2022JPMorgan Chase & Co.Lower TargetCHF 72.20 ➝ CHF 69
2/17/2022Credit Suisse GroupBoost TargetOutperform$93.00 ➝ $96.00
2/17/2022Morgan StanleyLower TargetEqual Weight$95.00 ➝ $92.00
1/18/2022StephensDowngradeOverweight ➝ Equal Weight$90.00 ➝ $86.00
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$95.00
11/12/2021Credit Suisse GroupBoost TargetOutperform$90.00 ➝ $93.00
11/11/2021JPMorgan Chase & Co.Reiterated RatingNeutral
11/11/2021CitigroupBoost TargetNeutral$84.00 ➝ $87.00
11/11/2021Morgan StanleyBoost TargetOverweight$92.00 ➝ $95.00
9/30/2021OppenheimerInitiated CoverageMarket Perform
9/13/2021Wells Fargo & CompanyBoost TargetOverweight$90.00 ➝ $93.00
8/27/2021Berenberg BankReiterated RatingBuy
8/23/2021UBS GroupUpgradeBuy
8/23/2021CitigroupBoost TargetNeutral$72.00 ➝ $84.00
8/20/2021Societe GeneraleReiterated RatingHold
8/19/2021JPMorgan Chase & Co.Reiterated RatingNeutral
8/19/2021Credit Suisse GroupBoost TargetOutperform$86.00 ➝ $90.00
8/19/2021Morgan StanleyBoost TargetOverweight$79.00 ➝ $92.00
8/19/2021Leerink PartnersBoost TargetPositive ➝ Market Perform$71.00 ➝ $82.00
8/19/2021Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$83.00 ➝ $90.00
8/19/2021StephensBoost TargetOverweight$79.00 ➝ $90.00
8/19/2021BTIG ResearchBoost TargetBuy$80.00 ➝ $84.00
7/14/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy$74.00
5/7/2021JPMorgan Chase & Co.Reiterated RatingNeutral
5/6/2021CitigroupUpgradeSell ➝ Neutral
4/1/2021Berenberg BankReiterated RatingBuy
3/31/2021ArgusBoost Target$72.00 ➝ $78.00
3/31/2021Jefferies Financial GroupBoost TargetBuy$82.00 ➝ $85.00
3/29/2021Societe GeneraleReiterated RatingHold
3/29/2021BTIG ResearchUpgradeNeutral ➝ Buy$78.00
3/25/2021Jefferies Financial GroupBoost TargetBuy$82.00 ➝ $85.00
3/22/2021BTIG ResearchUpgradeNeutral ➝ Buy$78.00
3/5/2021Berenberg BankReiterated RatingBuy
3/3/2021Credit Suisse GroupBoost TargetOutperform$76.00 ➝ $86.00
3/3/2021Morgan StanleyBoost TargetOverweight$75.00 ➝ $79.00
2/26/2021Societe GeneraleUpgradeSell ➝ Hold
2/25/2021Morgan StanleyReiterated RatingOverweight$75.00 ➝ $79.00
2/25/2021Credit Suisse GroupBoost TargetOutperform$76.00 ➝ $86.00
1/20/2021Berenberg BankReiterated RatingBuy
12/15/2020Morgan StanleyBoost TargetOverweight$73.00 ➝ $75.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2025
  • 6 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 4 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 7 very positive mentions
  • 38 positive mentions
  • 11 negative mentions
  • 2 very negative mentions
Mentions as of
9/5/2025
  • 6 very positive mentions
  • 27 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2025
  • 9 very positive mentions
  • 32 positive mentions
  • 9 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 11 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 11 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Alcon logo
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Read More

Today's Range

Now: $78.97
Low: $78.76
High: $79.93

50 Day Range

MA: $75.94
Low: $71.99
High: $80.03

52 Week Range

Now: $78.97
Low: $71.55
High: $99.20

Volume

866,226 shs

Average Volume

2,286,637 shs

Market Capitalization

$38.95 billion

P/E Ratio

37.60

Dividend Yield

N/A

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Alcon?

The following equities research analysts have issued research reports on Alcon in the last year: Bank of America Corporation, Barclays PLC, BTIG Research, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Hsbc Global Res, HSBC Holdings plc, JPMorgan Chase & Co., Kepler Capital Markets, KeyCorp, Mizuho, Morgan Stanley, Needham & Company LLC, Redburn Atlantic, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, UBS Group AG, Wall Street Zen, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for ALC.

What is the current price target for Alcon?

0 Wall Street analysts have set twelve-month price targets for Alcon in the last year. Their average twelve-month price target is $90.97, suggesting a possible upside of 15.2%. Sanford C. Bernstein has the highest price target set, predicting ALC will reach $101.09 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $77.53 for Alcon in the next year.
View the latest price targets for ALC.

What is the current consensus analyst rating for Alcon?

Alcon currently has 8 hold ratings, 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALC.

What other companies compete with Alcon?

Other companies that are similar to Alcon include Cooper Companies, DexCom, HCA Healthcare, Tenet Healthcare and Universal Health Services. Learn More about companies similar to Alcon.

How do I contact Alcon's investor relations team?

Alcon's physical mailing address is Rue Louis-d`Affry 6, Fribourg V8, 1701. The healthcare company's listed phone number is 418172930450 and its investor relations email address is [email protected]. The official website for Alcon is www.alcon.com. Learn More about contacing Alcon investor relations.